Ligand Pharmaceuticals
As of the edition of 20 October 2026, Ligand Pharmaceuticals runs 11 drugs, 5 of them marketed; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Ligand Pharmaceuticals was renamed in 1994.
The records place 5 company names in this family.
- Ligand Pharmaceuticals: renamed in 1994
- Neurogen Corporation: acquired in 2009; successor Ligand Pharmaceuticals
- Pfenex, Inc: acquired in 2020; successor Ligand Pharmaceuticals
- Apeiron Biologics: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 2 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Teriparatide | none listed | 3 |
| Acyclovir | none listed | 0 |
| Bexarotene | none listed | 6 |
| Alitretinoin | none listed | 0 |
| Sparsentan | Ends 2031 (exclusivity) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Ligand Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 8 trials led
- Bones, joints and muscles: 4 trials led
- Hormones: 3 trials led